Diagnostic evaluation of Fibrotest panel as a Biomarkers for the prediction of fatty liver disease: A Review Article

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially progressive disorder, representing a wide spectrum of disease from simple steatosis and different degrees of fibrosis to non-alcoholic steatohepatitis (NASH), and eventually cirrhosis. With a global prevalence of approximately 25%, NAFLD is now the leading cause of chronic liver disease worldwide and a growing challenge to public health. Haptoglobin, alpha2macroglobulin, apolipoprotein A1, play main roles in liver diseases, which can be analysed via blood tests which It is considered non-invasive method and replacement of liver fibro scan or biopsy. There are several drawbacks in using liver biopsy and Fibroscan for this purpose. Therefore, the needing for noninvasive diagnostic methods is urgent. this review would aim to focused on the crucial biomarkers related to the fibrosis stages progression.